Drugs / CC-93269
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03486067 | Apr 2018 → Mar 2025 | plasma cell myeloma | Celgene Corporation | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CC-93269 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03486067 ↗ |
| Route | Intravenous | “CC-93269 administered intravenous (IV)” NCT03486067 ↗ |